Claims

1. An aqueous pharmaceutical composition comprising between about 60 mg/ml and about 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, about 4.5% to 11% (w/v) sucrose, 5-20 mM sodium citrate, and 0.02% polysorbate 80 (w/v), wherein the pH of the composition is 7.2±1%.

2. The aqueous pharmaceutical composition according to claim 1, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 or 4.

3. The aqueous pharmaceutical composition according to claim 1 or 2, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 and 4.

4. The aqueous pharmaceutical composition of any one of claims 1 to 3, wherein the pH of the composition is 7.2.

5. The aqueous pharmaceutical composition of any one of claims 1 to 4, comprising between about 60 mg/ml and about 120 mg/ml of an anti-VEGF antibody.

6. The aqueous pharmaceutical composition of any one of claims 1 to 4, comprising about 20 mg/ml of an anti-VEGF antibody.

7. The aqueous pharmaceutical composition of any one of claims 1 to 6, comprising 5.5% to 7.0% (w/v) sucrose.

8. The aqueous pharmaceutical composition of claim 1, comprising 6.5% (w/v) sucrose, 12 mM sodium citrate, 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

9. The aqueous pharmaceutical composition of claim 8, comprising about 60 mg/ml of an anti-VEGF antibody.

10. The aqueous pharmaceutical composition of claim 8, comprising 3 mg of an anti-VEGF antibody.

11. The aqueous pharmaceutical composition of any of claim 1, comprising 5.8% (w/v) sucrose, 10 mM sodium citrate, 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

12. The aqueous pharmaceutical composition of claim 11, comprising about 120 mg/ml of an anti-VEGF antibody.

13. The aqueous pharmaceutical composition of claim 11, comprising 6 mg of an anti-VEGF antibody.

14. An aqueous pharmaceutical composition comprising 60 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 3 or SEQ ID NO: 4, 6.5% (w/v) sucrose, 12 mM sodium citrate, and 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

15. An aqueous pharmaceutical composition comprising 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 3 or SEQ ID NO: 4, comprising 5.8% (w/v) sucrose, 10 mM sodium citrate, and 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

16. The aqueous pharmaceutical composition of any one of claims 1 to 15, wherein said composition is stable for at least 18 months at 2-8°C.

17. The aqueous pharmaceutical composition of any one of claims 1 to 16, wherein said composition is liquid.

18. An aqueous pharmaceutical composition of any one of claims 1 to 17 for use in delivering an anti-VEGF antibody to a subject.

19. Use of the aqueous pharmaceutical composition of any one of claims 1 to 17 in the manufacture of a medicament for the treatment of an ocular disease or disorder that is mediated by VEGF.

20. The use according to claim 19, wherein said ocular disease or disorder is an ocular neovascular disease.

21. The use according to claims 19 or 20, wherein the aqueous pharmaceutical composition is to be administered to a subject, and wherein said administration is intravitreal.

22. A delivery device comprising the aqueous pharmaceutical composition of any one of claims 1 to 17.

23. The delivery device of claim 22, which is a pre-filled syringe.